Hjem › Burkitts lymfom › New York

Kliniske studier for Burkitts lymfom i New York

20 studier for Burkitts lymfom søker deltakere på steder i New York.

Byer i New York

Offisiell studietekst (engelsk)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
NYU Langone Hospital - Long Island, Mineola
og 9 flere

RekruttererFase 2

366 Days – 46 Years · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Roswell Park Cancer Institute, Buffalo
Northwell Health/Center for Advanced Medicine, Lake Success
North Shore University Hospital, Manhasset
og 4 flere

RekruttererFase 3

Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Northwell Health/Center for Advanced Medicine, Lake Success
North Shore University Hospital, Manhasset
Long Island Jewish Medical Center, New Hyde Park
og 2 flere

RekruttererFase 2

Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Albany Medical Center, Albany
Roswell Park Cancer Institute, Buffalo
The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
og 7 flere

RekruttererFase 2

365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

RekruttererFase 3

Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center, New York

RekruttererFase 3

Alder 1 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07223021

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Memorial Sloan Kettering Cancer Center ( Site 1010), New York
New York Medical College ( Site 1023), Valhalla

RekruttererFase 1/2

6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

The Mount Sinai Hospital, New York

RekruttererFase 1

Alder 0 til 18 · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06173518

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

RekruttererFase 1

Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
NYU Langone Hospital - Long Island, Mineola
og 7 flere

RekruttererFase 2

Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Albany Medical Center, Albany
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
og 12 flere

RekruttererFase 3

365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, New York

RekruttererFase 1/2

Alder 12 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT06137118

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

New York Medical College, Valhalla

RekruttererFase 1/2

Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

New York Medical Center, Valhalla

RekruttererFase 1/2

Alder 12 til 70 · Alle kjønn · Oppdatert 15. apr. 2026 · NCT04491370

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Memorial Sloan Kettering Cancer Center, New York

RekruttererFase 2

Alder 18 til 54 · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06918431

Study of SGR-1505 in Mature B-Cell Neoplasms

Roswell Park Comprehensive Cancer Center, Buffalo
Weill Cornell, New York
Montefiore Medical Center, The Bronx

RekruttererFase 1

Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT05544019

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Roswell Park Comprehensive Cancer Center, Buffalo

RekruttererFase 1

Alder 18 og eldre · Alle kjønn · Oppdatert 4. nov. 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Roswell Park Comprehensive Cancer Center, Buffalo
Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

RekruttererFase 1/2

Alder 15 til 50 · Alle kjønn · Oppdatert 9. sep. 2025 · NCT04150497

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College, Valhalla

RekruttererFase 2

Alder 3 til 31 · Alle kjønn · Oppdatert 8. aug. 2025 · NCT02393157

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Roswell Park Cancer Institute, Buffalo

RekruttererFase 2

Alder 1 til 25 · Alle kjønn · Oppdatert 4. mai 2025 · NCT03509961

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.